Kanptotezina eta haren deribatuak minbiziaren aurkako borrokanTopoisomerasa I inhibitzaileak
- Lopez-Aguileta, Leyre 1
- Alonso, Concepción 1
- Palacios, Francisco 1
- Selas, Asier 1
- Martín-Encinas, Endika 1
- 1 Euskal Herriko Unibertsitatea UPV/EHU
ISSN: 0214-9001
Ano de publicación: 2023
Número: 44
Páxinas: 127-136
Tipo: Artigo
Outras publicacións en: Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria
Resumo
ABSTRACT: Cancer has been identified as one of the leading causes of death worldwide, claiming almost 10 million lives by 2020, according to the WHO. The biological target of some anticancer agents is topoisomerase I, an enzyme involved in the relaxation of supercoiled DNA. The synthesis of new compounds that may behave as topoisomerase I inhibitors with antiproliferative effect has become an active field of research. Investigation related to topoisomerase I inhibitors in cancer therapy started with camptothecin (CPT). This compound was first selected as a good anticancer agent and then topoisomerase I was identified as its therapeutic target. CPT and its derivatives (irinotecan, topotecan and belotecan) are the only clinically approved inhibitors. Currently, their limitations are being addressed by means of the use of combination therapies with different drugs, drugs combined with antibodies, adoption of protocols to increase the bioavailability, such as administration of nanoparticles, emulsions, liposomes. Future studies should focus not only on developing other active molecules, but also on improving the bioavailability and pharmacokinetics of potent synthetic derivatives.